

Consultation on draft quality standard – deadline for comments 5pm on 19/10/18 email: QSconsultations@nice.org.uk

Ro	<p>Please read the checklist for submitting comments at the end of this form. We cannot accept forms that are not filled in correctly.</p> <p>We would like to hear your views on these questions:</p> <ol style="list-style-type: none"> 1. Does this draft quality standard accurately reflect the key areas for quality improvement? If the systems and structures were available, do you think it would be possible to collect the data for the proposed quality measures? Do you have an example from practice of implementing the NICE guideline(s) that underpins this quality standard? If so, please submit your example to the NICE local practice collection on the NICE website. Examples of using NICE quality standards can also be submitted. 2. For question 4, draft quality statement 1: To ensure this statement is practical and measurable, should it focus on particular vulnerable groups: people with chronic respiratory and cardiovascular conditions; children; pregnant women; older people? 3. For question 5, draft quality statement 1: To ensure this statement is practical and measurable, should it focus on providing advice at particular types of health appointment such as: initial antenatal booking appointments; child health checks; annual reviews for people with chronic respiratory or cardiovascular conditions; when presenting with an exacerbation of a respiratory or cardiovascular condition?
Organisation name – stakeholder or respondent (if you are responding as an individual rather than a registered stakeholder please leave blank):	[Royal Pharmaceutical Society]
Disclosure Please disclose any past or current, direct or indirect links to, or funding from, the tobacco industry.	[N/A]
Name of commentator person completing form:	[Yogeeta Bhupal-Professional Support Pharmacist]

Consultation on draft quality standard – deadline for comments 5pm on 19/10/18 email: QSconsultations@nice.org.uk

Supporting the quality standard - Would your organisation like to express an interest in formally supporting this quality standard? More information.		<input checked="" type="checkbox"/> [Yes]	
Type		[office use only]	
Comment number	Section	Statement number	Comments
<p style="text-align: center;">Insert each comment in a new row. Do not paste other tables into this table because your comments could get lost – type directly into this table.</p>			
	General		<p>The Royal Pharmaceutical Society is the professional body for pharmacists and pharmacy in Great Britain. As professionals in pharmaceutical care, pharmacists are well equipped to offer advice on health and wellbeing. With an increasing number of pharmacists working in general practice and managing long term conditions such chronic obstructive pulmonary disease (COPD), pharmacists are often directly involved in providing health and lifestyle advice for better management.</p>
1	Statement 1		<p>We support this statement in general. However NICE may need to consider the advice on how to minimise exposure and manage related symptoms. It may be useful to have support guidance for healthcare professionals with practical tips on how to support patients that are vulnerable. UK Air provide a daily air quality index with associated health advice (https://uk-air.defra.gov.uk/air-pollution/daqi). Currently the advice given may not always be feasible such as '<i>Close external doors and windows facing a busy street at times when traffic is heavy or congested to help stop highly polluted air getting in</i>'. This may prove difficult for families who live on busy main roads, particularly in the summer months. Additionally, further advice may be needed on '<i>Use an asthma reliever inhaler more often, as necessary</i>', as this may not be appropriate use of an asthma reliever. Asthma UK have a range of tips for asthmatics to manage their asthma on high pollution days. Further information can be found here:- https://www.asthma.org.uk/advice/triggers/pollution/#TopTips, this includes advice such as '<i>taking your preventer medicine every day you'll cope better with all your triggers, including pollution</i>'.</p>
2	Statement 2		No Comments
3	Statement 3		No Comments
4	Statement 4		No Comments

Consultation on draft quality standard – deadline for comments 5pm on 19/10/18 **email:** QSconsultations@nice.org.uk

Checklist for submitting comments

- Use this comment form and submit it as a Word document (not a PDF).
- Complete the disclosure about links with, or funding from, the tobacco industry.
- Include section number of the text each comment is about eg. introduction; quality statement 1; quality statement 2 (measure).
- If commenting on a specific quality statement, please indicate the particular sub-section (for example, statement, measure or audience descriptor).
- Combine all comments from your organisation into 1 response. We cannot accept more than 1 response from each organisation.
- Do not paste other tables into this table – type directly into the table.
- Underline and highlight any confidential information or other material that you do not wish to be made public.
- Do not include medical information about yourself or another person from which you or the person could be identified.
- Spell out any abbreviations you use
- For copyright reasons, comment forms do not include attachments such as research articles, letters or leaflets (for copyright reasons). We return comments forms that have attachments without reading them. The stakeholder may resubmit the form without attachments, but it must be received by the deadline.

You can see any guidance and quality standards that we have produced on topics related to this quality standard by checking [NICE Pathways](#).

Note: We reserve the right to summarise and edit comments received during consultations, or not to publish them at all, if we consider the comments are too long, or publication would be unlawful or otherwise inappropriate.

Comments received from registered stakeholders and respondents during our consultations are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the comments we received, and are not endorsed by NICE, its officers or advisory Committees.